Former title: Hormonal Regulation of Multidrug Resistance in Normal Rat Placental Tissues and Cells The commonly used spice and flavoring agent, rosemary, derived from the leaves of the plant Rosmarinus officinalis L. has important antioxidant activity. Although carnosol, carnosic acid, rosmaridiphenol, rosmanol, isorosmanol, epirosmanol, and rosmariquinone are antioxidant compounds in rosemary leaves [Nakatani, N. in: Huang et al. (eds), Phenolic compounds in Food and Their Effects on Health II: Antioxidants and Cancer Prevention, pp. 72-86. Washington, DC: American Chemical Society, 1992] about 90% of the antioxidant activity of rosemary can be attributed to carnosol and carnosic acid [Aruoma et al. (1932) Xenobiotic 22:257-268]. We have demonstrated that other antioxidants such as the flavonol, quercetin, are potent stimulators of adriamycin (Adr) efflux via a P-glycoprotein (P-gp)-mediated mechanism [Critchfield et al. (1994) Biochem. Pharm. 48:1437-1445]. We examined the the effect of rosemary in chemotherapeutic drug efflux mechanim in human breast cancer drug resistant cells. Rosemary extract was partially purified and the antioxidant activity evaluated by the Ames test. The effect of rosemary was studied in MCF-7 wild-type(WT), drug resistant subclone R65, and MDR1 transfected (Clone 10.9) MCF-7 cells. Interestingly, we found that rosemary extract when present in 330- or 1000-fold excess competed for azidopine labelling of P-gp. We further demonstrated that the rosemary markedly decreased the P-gp Adr efflux in P-gp expression R65 and Clone 10.9 but not WT MCF-7 cells. The cytotoxic effect of rosemary extract is extremely low as noted by the IC50 in WT and R65 cells of 125 mM and 150 mM,respectively. This is the first time that a natural product such as rosemary has been shown to inhibit P-gp mediated drug efflux. Our findings suggested that rosemary may serve as a MDR reversal agent for cancer chemotherapy. This project has been discontinued. - Adriamycin, Breast, carnosol, MCF-7, Rosemary,

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC000156-09
Application #
6289050
Study Section
Special Emphasis Panel (BRL)
Project Start
Project End
Budget Start
Budget End
Support Year
9
Fiscal Year
1999
Total Cost
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code